Abstract
Background Despite various therapeutic options, there is currently no cure for juvenile onset recurrent respiratory laryngeal papillomatosis (JORRP). Additionally, for the majority of these therapeutic options mild to severe side effects have been described. Objective Analysis of the effects and side effects of previous and current therapeutic options. Discussion of active ingredients, dosage and administrative form of the available drugs. Material and methods Review of literature and analysis of the therapeutic options concerning effects and side effects, active ingredients, dosage and administrative form. Results Surgery remains the gold standard of all treatment options. There are multiple therapeutic options in the literature; however, no treatment options currently lead to a complete remission. Maintaining the function, increasing the time interval between interventions and diminishing the papilloma load in cases of recurrence remain the utmost priority. Conclusion There are several promising therapeutic options for the treatment of JORRP; however, the current data situation is not sufficient for a general recommendation or guidelines. In the future, further prospective studies with a larger patient population/juvenile population are necessary.
Titel in Übersetzung | Juvenile laryngeal papillomatosis : Therapeutic options and review of literature |
---|---|
Originalsprache | Deutsch |
Seitenumfang | 5 |
Fachzeitschrift | Monatsschrift Kinderheilkunde |
DOIs | |
Publikationsstatus | Elektronische Veröffentlichung vor Drucklegung - Juni 2022 |
Extern publiziert | Ja |
Schlagwörter
- Bevacizumab
- Human papillomavirus
- Laryngeal papillomatosis
- Programmed cell death 1 receptor
- Vaccine